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Objective: Migration and proliferation of vascular smooth muscle cells (SMCs) contributes to intimal hyperplasia in
saphenous vein (SV) bypass grafts, which leads to patency-threatening stenosis. Evidence for the involvement of basement
membrane–degrading matrix metalloproteinases (MMPs) and growth factors in mediating SMC migration and prolif-
eration has been presented in a number of in vitro and in vivo models. 3-Hydroxy-3 methylglutaryl CoA reductase
inhibitors (statins) are widely used in patients with atherosclerosis and are claimed to have additional effects beyond
cholesterol reduction. We therefore examined the effects of simvastatin, a commonly prescribed statin, on the prolifer-
ation and migration of cultured human SV SMC and on neointima formation and MMP activity in human SV organ
cultures. To clarify its mode of action, we studied in parallel the effects of a specific MMP inhibitor, marimastat.
Study design: Human SV specimens were obtained from patients who underwent coronary artery bypass grafting, and
were cultured for 14 days in the presence of three concentrations of simvastatin and subsequently processed for
measurement of MMP activity and neointimal thickness measurements. Cultured SV SMCs were used to construct
growth curves in the presence of 10% fetal calf serum or 10% fetal calf serum supplemented with simvastatin or
marimastat. Migration through a Matrigel basement-membrane matrix (invasion) was quantified with modified Boyden
chambers.
Results: Simvastatin dose dependently reduced neointima formation (P  .004) in association with reduced MMP-9
activity (P  .03). SMC proliferation and invasion also were inhibited with simvastatin (P < .007 and P < .009,
respectively). Marimastat dose dependently inhibited SMC invasion (P < .001) but importantly had no effect on SMC
proliferation (P > .36).
Conclusion: For effective control of neointimal development in vivo, a pharmacologic strategy should inhibit both SMC
migration and proliferation. The ancillary properties of 3-Hydroxy-3 methylglutaryl CoA reductase inhibitors typified by
simvastatin may be important in this regard. (J Vasc Surg 2002;36:150-7.)
Patency-threatening stenosis affects as much as 40% of
saphenous vein (SV) bypass grafts.1 These stenoses result
from localized areas of intimal hyperplasia (IH), a lesion
characterized by smooth muscle cell (SMC) migration,
proliferation, and matrix remodeling.2
A prerequisite for SMC migration in vivo is degradation
of surrounding matrix proteins, a process accomplished
with secretion of specific matrix-degrading enzymes, matrix
metalloproteinases (MMPs), from the SMCs them-
selves.3-6 Previous studies by ourselves7 and other investi-
gators8 have shown increased production of MMP-9 (ge-
latinase B) and increased activation of MMP-2 (gelatinase
A) in organ-cultured human SV, a technique extensively
validated as a useful model of human vein graft IH.9,10 In
this model, the increases in gelatinolytic activity accompany
the development of neointimal thickening,7 which suggests
that raised levels of MMPs are functionally important in
mediating SMC migration and may play a significant role in
the development of vein graft stenosis.
In a previous study, we have shown that therapeutic
concentrations of the broad-spectrum MMP inhibitor ma-
rimastat can inhibit neointima formation in cultured hu-
man SV.11 This reduction was accompanied by decreased
gelatinolytic activity in the tissues. Gelatinases, in particular
MMP-9, are the principal MMPs involved in neointima
formation in human SV.7,8,11
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors
(statins) are a class of drugs used to reduce plasma choles-
terol levels in patients with hypercholesterolemia.12 Large
clinical trial results have related statin-induced cholesterol
lowering to the beneficial effect in patients with atheroscle-
rotic disease.13-15 The cellular effects of statins are the
result of inhibition of 3-Hydroxy-3 methylglutaryl CoA
reductase, a key enzyme in the mevalonate metabolic path-
way. Mevalonate is necessary for the production of choles-
terol but is also an important precursor of many isoprenoid
compounds that are necessary for posttranslational preny-
lation of a variety of proteins, and it appears that inhibition
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of protein prenylation is a key mechanism by which statins
affect SMC function.16-19 Indeed, statins have been shown
to decrease rat aortic SMC migration and proliferation
independently of cholesterol synthesis by interfering with
signaling pathways requiring prenylated proteins.20
A number of recent studies have reported that statins
can inhibit MMP-9 activity in monocytes,21 macro-
phages,22 fibroblasts,23 and breast cancer cell lines.24 Such
effects may also occur in other cell types, in particular the
vascular SMC. Because increased secretion of MMP-9 is a
feature of neointimal formation in organ-cultured human
SV,7,8,11 statins might offer a potential therapeutic benefit
in the prevention of IH. To further support a role for
MMP-9 in vascular disorders characterized by neointima
formation, another recent study found a polymorphism in
the promoter region of the MMP-9 gene that influenced its
expression, predisposing some individuals to more severe
atherosclerosis.25 The ability to regulate or control the
effects of MMP-9 overproduction in the vasculature could
be important in conditions characterized by IH.
It is interesting to note that GM-6001, a specific MMP
inhibitor, reduced SMC migration and early lesion forma-
tion in a rat angioplasty model.26 However, this reduction
was compensated with increased SMC proliferation, such
that neointimal size in the treated animals was no different
from controls after 14 days. This suggests that although
MMPs are important mediators of cell migration in vivo, a
combined antiproliferative and antimigratory strategy, such
as that offered by statins, may be more effective but remains
untested.
Therefore, the aim of this study was to examine the
effects of simvastatin, a commonly prescribed statin, on the
proliferation and invasion of cultured human SV SMC and
on neointima formation and gelatinase activity in human
SV organ cultures. To clarify its mode of action, we studied
in parallel the effects of marimastat, a specific MMP
inhibitor.
METHODS
Organ culture. Segments of the long SV were ob-
tained from 10 patients who underwent arterial bypass
grafting and were prepared for culture with a method
described previously.9 Local ethical committee approval
and patient consent were obtained. For each patient, four
equal individual segments were cultured in Roswell Park
Memorial Institute (RPMI)–1640 medium supplemented
with 30% fetal calf serum (FCS) for a period of 14 days. One
segment served as control (0.5% dimethyl sulfoxide vehi-
cle), and the remaining three were supplemented with
simvastatin (Merck, Sharpe & Dohme, Hoddesdon, Herts,
UK) at three different concentrations. With vein obtained
from five further patients, three segments from each were
cultured as either control, simvastatin, or simvastatin plus
mevalonate. Culture medium and drugs were replaced
every 2 days, and at the end of the culture period, the
segments were divided in half. One half was fixed in 4%
paraformaldehyde for 18 hours, processed, paraffin-em-
bedded, and sectioned to 4 m. The remaining half was
immediately snap-frozen in liquid nitrogen and stored at
–80° C for subsequent metalloproteinase extraction and
gelatin zymography.
Gelatin zymography. Metalloproteinases were ex-
tracted from the frozen tissues27 and protein standardized
to 0.9 mg/mL. Zymography was performed on each sam-
ple with nonreducing electrophoresis through a 10% so-
dium dodecylsulfate–polyacrylamide gel impregnated with
1 mg/mL gelatin.27 As a positive control, conditioned
medium from a human fibrosarcoma cell line (HT-1080)
also was loaded onto each gel. On completion of the
separation, sodium dodecylsulfate was removed from the
gels with incubation in 2.5% Triton X-100 (3 15 min-
utes) (Sigma, Poole, UK) before immersion for 18 hours in
incubation buffer (50 mmol/L Tris-HCl, 10 mmol/L
CaCl2, and 0.05% Brij-35, pH 7.4) at 37° C. Gels then
were fixed and stained in 0.1% Coomassie brilliant blue
(Sigma) in 50% methanol/20% acetic acid/30% double
distilled water for 2 to 3 hours. Proteinases were visualized
as clear bands of lysis against a dark blue background of
intact substrate. The molecular weight of each band was
estimated by comparison with known molecular weight
standards (Bio-Rad, Hemel Hempstead, Herts, UK). The
relative density of each lytic band was determined from
negative photographic images of gels with a scanning den-
sitometer (Pharmacia LKB, St Albans, Herts, UK) and
expressed as a product of optical density and area of the
band. To allow for variation between gels, samples from
within the same experimental group were run on the same
gel and paired statistics used in the analysis.
Immunohistochemistry and neointima measure-
ments. Standard morphometric measurements were per-
formed on histologic cross sections of cultured SV seg-
ments stained with anti- smooth muscle actin. This
method uses an indirect immunoperoxidase technique,
with diaminobenzidine as the final reaction product. This
was followed with application of Miller’s elastin stain to
localize the internal elastic lamina. The neointimal thick-
ness was determined with an average of 30 measurements
across the entire length of two consecutive sections for each
vein segment, as we have described previously.9
Smooth muscle cell isolation and culture. Human
SV SMCs were prepared with an explant technique. SV
segments were chopped into small fragments (approxi-
mately 1 mm3) within a 2-mL volume of RPMI medium
supplemented with 10% FCS. The vein fragments together
with the medium were transferred to 25-cm2 tissue culture
flasks and maintained at 37°C in a humidified incubator in
5% CO2 in air. After 1 to 2 weeks, SMCs were seen to
migrate out from the explants, and at 4 to 5 weeks, cells
were passaged into 80-cm2 flasks and grown to confluence.
SMCs were characterized by their typical “hill and valley”
growth pattern in culture and by immunostaining with
anti- smooth muscle actin. All SMCs for proliferation and
migration experiments were used at passage 1.
Smooth muscle cell proliferation assays. For growth
inhibition experiments, SMCs were rendered quiescent in
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0.4% FCS for 72 hours and then trypsinized and plated into
24-well tissue culture plates at a density of 1104 cells per
well in 10% FCS-RPMI medium (control) or medium
supplemented with appropriate concentrations of either
simvastatin or marimastat. Medium and drugs were re-
placed every 2 days. Cell number was determined in dupli-
cate wells with a hemocytometer, and counts were made
every 2 days for 10 days to construct growth curves.
Growth curves were constructed with five separate SMC
populations for each drug. Neither simvastatin nor mari-
mastat had significant effects on cell viability, as determined
with Trypan Blue exclusion and with counting of detached
cells in the medium (data not shown).
Smooth muscle cell invasion assays. The ability of
SMC to migrate across a matrix barrier towards a chemo-
tactic stimulus (ie, cell invasion) was investigated with a
modified Boyden chamber technique. This was achieved
with 24-well tissue culture plates with inserts containing an
8-m pore-size polycarbonate membrane (Falcon). The
membranes were coated before use with 65-g/cm2 Ma-
trigel (BD Biosciences, Cowley, Oxford, UK), an artificial
basement membrane matrix. The inclusion of Matrigel in
our model more closely represents the in vivo situation,
where digestion of basement membrane matrix by the
SMCs themselves is a prerequisite for proliferation and
migration.3 SMCs were quiesced in medium containing
0.4% FCS for 72 hours, trypsinized, and resuspended in
Dulbecco’s modified Eagle’s medium supplemented with
0.25% bovine serum albumin (migration medium). Plate-
let-derived growth factor (PDGF) was prepared at 10
ng/mL in migration medium and loaded (750L) into the
lower wells, and control wells were loaded with migration
medium alone. SMCs were subsequently loaded into the
upper wells (1 105 cells in 500 L). Simvastatin or
marimastat at the appropriate concentration was added to
the upper and lower chambers of the experimental wells.
Plates then were incubated for 24 hours at 37°C in 5% CO2
in air. The cell suspension was aspirated, and the mem-
branes were fixed in 70% ethanol at20°C for 30 minutes.
The upper side of the membranes then were rubbed with a
moist cotton swab to remove cells that had attached but not
migrated. The membranes were rinsed in water, and mi-
grated cells on the underside of the membrane were visu-
alized with staining for 30 seconds each in hematoxylin and
eosin. The membranes then were detached from the inserts
and mounted for microscopic examination. Cell nuclei on
the underside of each membrane were counted in 10 ran-
dom high power fields (400) with a light microscope.
SMC invasion in the experimental groups was expressed as
the mean number of migrated cells per high power field.
Each duplicate assay was repeated five times on separate
occasions with different SMC preparations.
Data analysis. For the neointimal thickness and zy-
mography quantification, paired analysis between groups
was performed with the Wilcoxon paired rank test. For the
invasion experiments, mean differences between the treat-
ment groups were compared with Student paired t test. For
the proliferation assays, the areas under curves were calcu-
lated and means were compared with Student t test. The
proliferation data also were compared with a one-way anal-
ysis of variance (ANOVA) method. All statistical analyses
were performed with GraphPad Prism version 3.02 for
Windows (GraphPad Software, San Diego, Calif), with
significance assumed at the 95% confidence level (P .05).
RESULTS
Effect of simvastatin on neointimal thickness
All control veins developed a significant neointima,
with a median thickness of 19.3 m. Simvastatin attenu-
ated neointima formation at all three concentrations in a
dose-dependent manner (Fig 1). The median neointimal
thickness for the 0.5-mol/L, 1-mol/L, and 5-mol/L
groups was 8.0 m, 6.2 m, and 4.9 m, respectively,
which represented reductions in neointimal size of 59%,
68%, and 75%, respectively. This was statistically significant
(P  .004) at all three concentrations.
Effect of simvastatin on matrix metalloproteinase
levels
Fig 2, A, shows a representative gelatin zymogram for
control and simvastatin-treated veins. Bands of lysis were
consistently observed at 92 kDa, 72 kDa, and 66 kDa.
Immunoblotting results confirmed that these bands corre-
sponded to MMP-9, pro–MMP-2, and MMP-2, respec-
tively (data not shown). Simvastatin reduced the tissue
levels of MMP-9 at all the concentrations studied but had
no effect on tissue levels of MMP-2. Densitometric values
were expressed as a ratio of levels observed in control
HT-1080 cells. The median ratio for MMP-9 in the control
group was 1.37. The ratio was reduced in the simvastatin-
treated groups to 1.08 (0.5 mol/L), 0.67 (1 mol/L),
and 0.68 (5 mol/L; Fig 2, B). The reduction was signif-
icant at all three concentrations (P  .03 versus control in
all comparisons).
Fig 1. Simvastatin reduces neointimal thickness. Veins were
cultured for 14 days in medium alone (control) or in presence of
indicated concentrations of simvastatin before measuring neo-
intimal thickness. Horizontal bars represent median values. **P 
.01, compared with control.
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Reversal of the effects of simvastatin with mevalonate
The addition of mevalonate to segments of vein cul-
tured in the presence of 1-mol/L simvastatin restored the
development of neointima (Fig 3, A). The median thick-
ness of control segments was 19.7 m versus 6.6 m in the
simvastatin-treated group (P  .007). Mevalonate supple-
mentation restored neointimal thickening to a median of
18.0 m, a level not significantly different from control
(P  .54). Fig 3, B, shows a representative gelatin zymo-
gram for vein segments treated with 1-mol/L simvastatin
or with 1-mol/L simvastatin together with 100-mol/L
mevalonate. A significant band at 92 kDa (MMP-9), similar
to that observed in controls, can be clearly observed in the
presence of mevalonate.
Effect of simvastatin and marimastat on smooth
muscle cell proliferation
SMC growth in the presence and absence of simvastatin
or marimastat was evaluated during a 10-day period. Pro-
liferation was quantified with measurement of the area
under the growth curves.
Simvastatin. Simvastatin significantly inhibited SMC
proliferation (P  .004, with ANOVA; Fig 4, A). The
mean area under the curve for the 10% FCS control was
97.1 3.4. In the presence of simvastatin, the mean areas
under the curve were 66.2 4.7 (P  .0007, with Student
t test), 52.73.7 (P .0001), and 8.2 1.2 (P .0001)
for 0.5-mol/L, 1-mol/L, and 5-mol/L simvastatin,
respectively, which represented growth inhibition of 32%,
46%, and 92%, respectively.
Marimastat. Marimastat had no significant effect on
SMC proliferation (P .975, with ANOVA; Fig 4, B). The
mean area under the curve for the 10% FCS control was
47.5  5.1. In the presence of marimastat, the mean areas
under the curve were 43.5  4.6 (P  .44, with Student t
test), 40.2  5.5 (P  .36), and 41.8  4.9 (P  .57) for
0.1-mol/L, 1-mol/L, and 10-mol/L marimastat, re-
spectively.
Fig 2. Simvastatin reduces tissue levels of matrix metalloprotein-
ase (MMP)–9. A, Representative gelatin zymogram of saphenous
vein extracts from control and simvastatin-treated groups. Bands
of lysis were observed at 92 kDa (MMP-9), 72 kDa (pro–MMP-2),
and 66 kDa (MMP-2). Conditioned medium from HT-1080 cells
was included as positive control. B, Graphic representation of
densitometric values of MMP-9 levels for control and simvastatin-
treated vein segments. Values are expressed as ratio to control
HT-1080 cells, and horizontal bars represent median values. *P
.05, compared with control.
Fig 3. Mevalonate reverses effects of simvastatin on neointimal
thickness and matrix metalloproteinase (MMP)–9 activity. A, Scat-
ter plot shows neointimal thickness measurements of vein seg-
ments treated with 1-mol/L simvastatin or 1-mol/L simvasta-
tin plus 100-mol/L mevalonate for 14 days. Horizontal bars
represent median values. B, Representative gelatin zymogram of
vein extracts after treatment with 1-mol/L simvastatin or
1-mol/L simvastatin plus 100-mol/L mevalonate for 14 days.
**P  .01. NS, Not significantly different compared with
control.
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Effect of simvastatin and marimastat on smooth
muscle cell invasion
In agreement with other reports,28 SMC migration was
stimulated by PDGF at a maximally effective concentration
of 10 ng/mL (data not shown). Neither simvastatin nor
marimastat altered SMC attachment to the upper side of
the membrane (data not shown).
Fig 5, A, shows a representative microscopic field of
SMCs that have invaded the Matrigel and migrated towards
PDGF in the presence and absence of simvastatin or mari-
mastat. In the absence of chemoattractant in the lower
chamber, few SMCs (range, 0.0 to 2.2) migrated to the
underside of the membranes.
Fig 4. Effects of simvastatin and marimastat on serum-induced
saphenous vein smooth muscle cell proliferation. Cells were
treated with 10% fetal calf serum (FCS) alone (control) or 10% FCS
supplemented with indicated concentrations of simvastatin or ma-
rimastat for 10 days and counted every 48 hours. Data are ex-
pressed as mean standard error of mean of cell number. A, Cells
were treated with 10% FCS alone (open circles) or 10% FCS
supplemented with 0.5-mol/L (filled circles), 1-mol/L (filled
triangles), or 5-mol/L (filled squares) simvastatin. Statistical
analysis was performed on areas under curves. B, Cells were treated
with 10% FCS alone (open circles) or 10% FCS supplemented with
0.1-mol/L (filled circles), 1-mol/L (filled triangles), or 10-
mol/L (filled squares) marimastat. Statistical analysis was per-
formed on areas under curves. Marimastat had no statistically
significant effect compared with control at any of concentrations
tested. ***P  .001, compared with control.
Fig 5. Effect of simvastatin and marimastat on platelet-dervied
growth factor (PDGF)–induced saphenous vein smooth muscle
cell (SMC) migration. A, Representative high power fields (200
magnification) of SMC migrating to underside of membrane in
response to 10-ng/mL PDGF in presence or absence of 1-mol/L
simvastatin or 1-mol/L marimastat. Quantification of SMC mi-
gration in response to 10-ng/mL PDGF in presence of increasing
concentrations of simvastatin (B) or marimastat (C). Data are
expressed as mean standard error of mean of number of migrated
cells per high power field. **P  .01. ***P  .001. NS, Not
significantly different compared with PDGF alone.
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Simvastatin. Cell invasion induced with PDGF was
dose dependently inhibited with simvastatin (Fig 5, B). The
number of invasive SMCs was reduced by 54% (P .009),
69% (P  .004), and 76% (P  .002) for 0.5-mol/L,
1-mol/L, and 5-mol/L simvastatin, respectively.
Marimastat. Marimastat also caused a dose-depen-
dent inhibition of PDGF-induced invasion (Fig 5, C).
Marimastat at concentrations of 0.1 mol/L, 1 mol/L,
and 10 mol/L reduced invasion by 22% (P  .05), 45%
(P  .001), and 56% (P  .0004), respectively.
DISCUSSION
Treatment with simvastatin caused a dose-dependent
inhibition of MMP-9 activity and a reduction of neointima
formation in cultured human SV segments. Furthermore,
mevalonate supplementation completely restored this neo-
intimal thickening in the cultured veins to a level indistin-
guishable from controls. These data indicate a key role for
MMP-9 activation in the process of neointima formation,
extending our earlier study with the broad-spectrum MMP
inhibitor marimastat.11 Importantly, with isolated SV
SMC, we have shown in this study that both simvastatin
and marimastat dose dependently inhibit SMC invasion
(migration across a Matrigel barrier), which shows that
both drugs are targeting MMPs needed for matrix degra-
dation before SMC migration. The observations made in
this study with simvastatin accord with those of Bellosta
and colleagues,22 who showed that simvastatin reduced
MMP-9 secretion by macrophages and that this was com-
pletely reversible by the addition of mevalonate. However,
the concentrations of simvastatin used in Bellosta et al’s22
study were considerably higher (as much as 100 mol/L)
than those used in our own study, and we observed that
simvastatin at concentrations in excess of 10 mol/L had
detrimental effects on cell viability in SV organ cultures and
isolated SV SMC (data not shown). Confirming our own
findings, Laufs et al19 also previously reported adverse
effects of simvastatin on human vascular SMC viability at
concentrations in excess of 20 mol/L.19 The lowest con-
centration used in our study (0.5 mol/L) was within the
therapeutic range and reflects the peak plasma concentra-
tions achieved after a single oral administration of 40 mg
(Merck Sharpe & Dohme, unpublished data, 1999).
A recent study by Mason and colleagues29 showed that
overexpression of MMP-9 enhanced SMC migration in
Matrigel invasion assays and in arterial remodeling of the
rat carotid artery. Although healthy SMCs do not produce
MMP-9 in quiescent conditions, George, Zaltsman, and
Newby8 showed that surgical preparative injury of the
human SV led to increased MMP-9 activity associated with
increased SMC proliferation.8 There is also agreement that
MMP-9 levels rise rapidly after balloon injury to rat and
rabbit arteries3,28 and after vein grafting in pigs.30
Our observations that simvastatin reduced proliferation
of cultured human SV SMC are in agreement with a recent
report that showed a reduction in the proliferation of rat
aortic SMC during a 6-day period with 2-mol/L simva-
statin.31 Furthermore, Laufs and colleagues19 have shown
that simvastatin dose dependently decreases DNA synthesis
after 24 hours in human vascular SMCs, although the
longer term effects of simvastatin on cell proliferation were
not investigated.
Recent clinical data suggest that some of the beneficial
effects of treatment with statins occur independently of
changes in serum cholesterol levels, through a direct effect
on the vascular wall.32 In this study, cultured SMCs were
maintained in serum-supplemented medium, which itself
provides an exogenous source of cholesterol. With these
conditions, simvastatin still inhibited proliferation, proba-
bly because of its inhibitory effects on the intracellular
signaling pathways involving protein prenylation. Meval-
onate is the precursor of several isoprenoid intermediates
that are important for the posttranslational modification of
a variety of proteins, including small Guanine nucleotide-
binding proteins (G-proteins). Prenylation of these small
G-proteins, which include the Ras and Rho families, is
essential for their membrane localization and function.33
Both of these small G-protein families have been shown to
be important in the mechanisms of vascular SMC prolifer-
ation, migration, and neointima formation.18,34,35 The
inhibitory effects of statins on vascular SMC proliferation
appear to be attributable to inhibition of either Ras or Rho
prenylation.17-19 However, the mechanisms by which st-
atins inhibit cell invasion have yet to be fully elucidated.
Invasion requires two distinct phases: degradation of the
basement membrane and migration towards a chemotactic
stimulus. Statins have been shown to reduce the latter of
these two processes in other cell types via a mechanism
involving inhibition of Rho prenylation and subsequent
disruption of the cytoskeleton.24,36 However, it is likely
that statins also decrease cell invasion by inhibiting MMP-9
activity and thereby the capacity of SMCs to degrade the
basement membrane. Statins have been shown to reduce
MMP-9 activity in several different cell types.21-24 However,
this study is the first to report this effect in human vascular
SMC.
There are few studies (none in vascular SMC) that
propose a mechanism to explain the inhibitory effects of
statins on MMP-9 activity.22,23 In murine NIH 3T3 fibro-
blasts, lovastatin reduces MMP-9 activity by reducing
MMP-9 gene expression.23 However, in monocyte-derived
macrophages, the inhibitory effects of statins on MMP-9
activity are not caused by changes in gene expression or
proteolytic cleavage of pro–MMP-9.22 In the absence of an
effect on gene expression or proteolytic activation, the
authors concluded that statins might be inhibiting factors
essential for the MMP-9 secretory process.22 We currently
are investigating the mechanism by which statins inhibit
MMP-9 activity in human SV SMC.
In contrast to simvastatin, marimastat is a specific and
potent inhibitor of MMPs. Hence, this compound should
not modulate SMC proliferation in vitro. In this study,
marimastat did not reduce proliferation, despite our earlier
observations showing that this drug could reduce neointi-
mal thickening and MMP-9 activity in SV organ cultures.13
Our observations in primary human tissue are in agreement
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with those of Zempo and colleagues,28 who showed that
although the potent MMP inhibitor batimastat inhibited
rat aortic SMC migration through Matrigel, it had no effect
on SMC proliferation.28 However, a more recent study
reported that batimastat does inhibit rat aortic SMC prolif-
eration,37 which suggests that in certain conditions MMPs
may serve as growth factors for SMC.38
A recent clinical study described treatment of patients
with simvastatin for 3 months before and after coronary
artery bypass surgery.39 At 1-year follow-up examination,
the patients with simvastatin treatment had a lower inci-
dence of SV graft lesions than did an untreated control
group. In addition, Hagenaars and colleagues40 reported
that simvastatin therapy had a beneficial effect after angio-
plasty of the femoropopliteal artery for arterial obstruction.
At 1-year follow-up examination, the patients with simva-
statin had increased lumen area in the angioplastied vessel
as compared with a control group. The beneficial effects
were attributed to simvastatin’s ability to induce “positive”
vascular remodeling, thereby reducing stenosis. In the light
of these two studies, we would propose that the observed
protective effects of simvastatin may be caused, at least in
part, by its antiinvasive and antiproliferative action at the
level of the SMC.
Although statins have been shown to reduce IH in
some animal models,41,42 our observations provide the first
report in human vascular tissue. Animal studies do repre-
sent useful models. However, it is important to be aware of
their limitations and the fact that observations made in
animal studies relating to the inhibition of IH are not
always reproducible in man.43 Although the organ culture
model used in this study is somewhat removed from the
clinical scenario, it uses the exact tissue that causes the clinical
problem in vivo, namely the human long SV. In addition,
cell-cell and cell-matrix interactions can be maintained in this
model.9 Moreover, the inclusion of Matrigel basement mem-
brane in our invasion studies more closely mimics the in vivo
situation than do basic chemotactic studies in which cell
migration occurs independently of MMP activity.18,44
Thus, our findings represent an important contribution to
our understanding of the role of statins as potential thera-
peutic agents for the prevention of IH in man.
In conclusion, our previous11 and present observations
show that increased MMP-9 proteolytic activity may con-
tribute to IH in human SV grafts. Both simvastatin and
marimastat ameliorated this response by reducing MMP-9
activity and SMC invasion. An additional property of sim-
vastatin, but not marimastat, was substantial inhibition of
SMC proliferation. Because IH is the result of both SMC
proliferation and migration, a combined antiproliferative
and antimigratory strategy, such as that offered with sim-
vastatin, may provide a more promising therapeutic ap-
proach to the prevention of stenosis in SV grafts.
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